You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Polaris Venture Partners VI | 1,697,924 | 1,697,924 | 1,697,924 | 4.1% | ||
Polaris Venture Founders 146 Fund VI | 99,220 | 99,220 | 99,220 | 0.2% | ||
Polaris Venture Management Co. VI | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
Jonathan A. Flint ( 147 Flint 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
Terrance G. McGuire ( 147 McGuire 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
Brian Chee ( 147 Chee 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
David Barrett ( 147 Barrett 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
Amir Nashat ( 147 Nashat 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% | ||
Bryce Youngren ( 147 Youngren 148 ) | 1,797,144 | 1,797,144 | 1,797,144 | 4.3% |
Page 1 of 14 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 3)*
EDITAS
MEDICINE, INC.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
28106W103
(CUSIP Number)
Polaris Partners One Marina Park Drive 10th Floor Boston, MA | Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP One Marina Park Drive, Suite 900 Boston, MA 02210 Attn: (617) 648-9100 |
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
September 8, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box: ☐
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.
* | The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. |
The information required on the remainder of this cover page
shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 2 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Polaris Venture Partners VI, L.P. (PVP | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) WC | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,697,924 shares, except that (i) Polaris Venture Management Co. VI, L.L.C. (PVM | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,697,924 shares, except that (i) PVM VI, the general partner of PVP VI, may be deemed to | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,697,924 | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.1% | |||||
14. | Type of Reporting Person (See PN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 3 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Polaris Venture Founders Fund VI, L.P. (PVPFF | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) WC | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 99,220 shares, except that (i) PVM VI, the general partner of PVPFF VI, may be deemed to | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 99,220 shares, except that (i) PVM VI, the general partner of PVPFF VI, may be deemed to | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 99,220 | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 0.2% | |||||
14. | Type of Reporting Person (See PN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 4 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Polaris Venture Management Co. VI, L.L.C. (PVM | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of Delaware | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See OO |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 5 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Jonathan A. Flint (Flint) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 6 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Terrance G. McGuire (McGuire) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 7 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Brian Chee (Chee) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 8 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of David Barrett (Barrett) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 9 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Amir Nashat (Nashat) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 10 of 14 – SEC Filing
CUSIP No. 28106W103 |
1. | Names of Bryce Youngren (Youngren) | |||||
2. | Check the Appropriate Box if a Member (a) ☐ (b) ☒ | |||||
3. | SEC Use Only | |||||
4. | Source of Funds (See Instructions) AF | |||||
5. | Check if Disclosure of Legal ☐ | |||||
6. | Citizenship or Place of USA | |||||
Number of Shares Beneficially Owned by Each Reporting Person With | 7. | Sole Voting Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | ||||
8. | Shared Voting Power See response to row 7. | |||||
9. | Sole Dispositive Power 1,797,144 shares, of which 1,697,924 shares are directly owned by PVP VI and 99,220 | |||||
10. | Shared Dispositive Power See response to row 9. | |||||
11. | Aggregate Amount Beneficially Owned by Each Reporting Person 1,797,144 shares | |||||
12. | Check if the Aggregate Amount in Row ☐ | |||||
13. | Percent of Class Represented by Amount 4.3% | |||||
14. | Type of Reporting Person (See IN |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 11 of 14 – SEC Filing
CUSIP No. 28106W103
SCHEDULE 13D
This Amendment No. 3
(Amendment No. 3) amends and supplements the Schedule 13D originally filed with the Securities and Exchange Commission (the SEC) on May 16, 2016 (the Schedule 13D), Amendment No. 1 to the Schedule
13D filed with the SEC on September 19, 2016 and Amendment No. 2 (Amendment No. 2) to the Schedule 13D filed with the SEC on May 22, 2017, by Polaris Venture Partners VI, L.P. (PVP VI), Polaris Venture
Founders Fund VI, L.P. (PVPFF VI), Polaris Venture Management Co. VI, L.L.C. (PVM VI), Jonathan A. Flint (Flint), Terrance G. McGuire (McGuire), Brian Chee (Chee), David Barrett
(Barrett), Amir Nashat (Nashat) and Bryce Youngren (Youngren and together with, PVP VI, PVPFF VI, PVM VI, Flint, McGuire, Chee, Barrett, and Nashat, collectively, the Reporting Persons), with respect
to shares of Common Stock of the Issuer beneficially owned by the Reporting Persons. This Amendment No. 3 is being filed to report the disposition of Common Stock by PVP VI and PVPFF VI on September 1, 2017, September 5, 2017,
September 7, 2017, September 8, 2017, September 11, 2017, September 12, 2017, September 13, 2017 and September 14, 2017; all other information is as set forth in the Schedule 13D, Amendment No. 1 and Amendment
No. 2. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Schedule 13D.
Item 4. Purpose of Transaction.
Item 4 of the Original
Schedule 13D is hereby amended to add the following statements:
On September 1, 2017, PVP VI sold 70,859 shares of Common Stock on the open market
and PVPFF VI sold 4,141 shares of Common Stock on the open market.
On September 5, 2017, PVP VI sold 141,412 shares of Common Stock on the open
market and PVPFF VI sold 8,264 shares of Common Stock on the open market.
On September 7, 2017, PVP VI sold 118,337 shares of Common Stock on the
open market and PVPFF VI sold 6,915 shares of Common Stock on the open market.
On September 8, 2017, PVP VI sold 142,986 shares of Common Stock on
the open market and PVPFF VI sold 8,356 shares of Common Stock on the open market.
On September 11, 2017, PVP VI sold 82,609 shares of Common Stock
on the open market and PVPFF VI sold 4,827 shares of Common Stock on the open market.
On September 12, 2017, PVP VI sold 13,778 shares of Common
Stock on the open market and PVPFF VI sold 805 shares of Common Stock on the open market.
On September 13, 2017, PVP VI sold 212,578 shares of
Common Stock on the open market and PVPFF VI sold 12,422 shares of Common Stock on the open market.
On September 14, 2017, PVP VI sold 162,231
shares of Common Stock on the open market and PVPFF VI sold 9,480 shares of Common Stock on the open market.
Item 5. Interest in Securities of the
Issuer.
Items 5(a) and (c) of the Schedule 13D are hereby amended and restated in their entirety as follows:
The information below is based on a total of 41,627,446 shares of Common Stock outstanding as reported on Form 10-Q,
Quarterly Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1934 filed with the Securities and Exchange Commission by the Issuer on August 9, 2017.
(a) | PVP VI directly beneficially owns 1,697,924 shares of Common Stock, or approximately 4.1% of the Common Stock outstanding. PVPFF VI directly beneficially owns 99,220 shares of Common Stock, or approximately 0.2% of the Common Stock outstanding. PVM VI, as the general partner of PVP VI and PVPFF VI, may be deemed to indirectly beneficially own the securities owned by PVP VI and PVPFF VI. PVM VI, as general partner of PVP VI and PVPFF VI may be deemed to indirectly beneficially own 1,797,144 shares of Common Stock, or approximately 4.3% of the Common Stock outstanding. Each of the Managing Members, in their respective capacities as managing members of PVM VI, may be deemed to indirectly beneficially own 1,797,144 shares of Common Stock, or approximately 4.3% of the Common Stock outstanding, aggregately owned by PVP VI and PVPFF VI. |
(c) | Except as described in this statement and this Item 5(c), none of the Reporting Persons has effected any transactions in the Common Stock in the 60 days prior to the date of this statement. |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 12 of 14 – SEC Filing
Item 7. Material to be Filed as Exhibits.
Exhibit | Description | |
A | Agreement Regarding the Joint Filing of Schedule 13D |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 13 of 14 – SEC Filing
CUSIP No. 28106W103
SIGNATURE
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date:
September 18, 2017
POLARIS VENTURE PARTNERS VI, L.P. | ||
By: | Polaris Venture Management Co. VI, L.L.C. | |
By: | * | |
Authorized Signatory | ||
POLARIS VENTURE PARTNERS FOUNDERS FUND VI, L.P. | ||
By: | Polaris Venture Management Co. VI, L.L.C. | |
By: | * | |
Authorized Signatory | ||
POLARIS VENTURE MANAGEMENT CO. VI, L.L.C. | ||
* | ||
Authorized Signatory | ||
JONATHAN A. FLINT | ||
By: | * | |
Jonathan A. Flint | ||
TERRANCE G. MCGUIRE | ||
By: | * | |
Terrance G. McGuire | ||
BRIAN CHEE | ||
By: | * | |
Brian Chee |
Follow Editas Medicine Inc.
Follow Editas Medicine Inc.
Page 14 of 14 – SEC Filing
CUSIP No. 28106W103
DAVID BARRETT | ||
By: | * | |
David Barrett | ||
AMIR NASHAT | ||
By: | * | |
Amir Nashat | ||
BRYCE YOUNGREN | ||
By: | * | |
Bryce Youngren |
*By: | /s/ Max Eisenberg | |
Name: | Max Eisenberg | |
Attorney-in-Fact |
[This Schedule 13D was executed pursuant to a Power of Attorney. Note that copies of the applicable Powers of Attorney are
already on file with the appropriate agencies.]